Literature DB >> 26898369

Urine proteome analysis as a discovery tool in patients with deep vein thrombosis and pulmonary embolism.

Constantin von Zur Mühlen1, Thomas Koeck2, Eric Schiffer2, Christine Sackmann1, Petra Zürbig2, Ingo Hilgendorf1, Jochen Reinöhl1, Jennifer Rivera3, Andreas Zirlik1, Christoph Hehrlein1, Harald Mischak2,4, Christoph Bode1, Karlheinz Peter3.   

Abstract

PURPOSE: Early and accurate detection of deep vein thrombosis (DVT) is an important clinical need. Based on the hypothesis that urinary peptides may hold information on DVT in conjunction with pulmonary embolism (PE), the study was aimed at identifying such peptide biomarkers using capillary electrophoresis coupled mass spectrometry. EXPERIMENTAL
DESIGN: Patients with symptoms of unprovoked/idiopathic DVT and/or PE were examined by doppler-sonography or angio-computed tomography. Urinary proteome analysis allowed for identification of respective peptide biomarkers. To confirm their biological relevance, we induced PE in mice and assessed human ex vivo thrombi.
RESULTS: We identified 62 urinary peptides as DVT-specific biomarkers, i.e. fragments of collagen type I and a fragment of fibrinogen β-chain. The presence of fibrinogen α/β in the acute thrombus, and collagen type I and osteopontin in the older, organized thrombus was demonstrated. The classifier DVT62 established through support vector machine (SVM) modeling based on the 62 identified peptides was validated in an independent cohort of 47 subjects (six cases and 41 controls) with a sensitivity of 100% and specificity of 83%. CONCLUSIONS AND CLINICAL RELEVANCE: Urine proteome analysis enabled the detection of DVT-specific peptides, which were validated in human and mouse tissue. Furthermore, it allowed for the establishment of an urinary-proteome based classifier that is relatively specific for DVT. The data provide the basis for assessment of these biomarkers in a prospective clinical study.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Biomarker; Discovery Tool; Pulmonary Embolism; Thrombosis

Mesh:

Substances:

Year:  2016        PMID: 26898369     DOI: 10.1002/prca.201500105

Source DB:  PubMed          Journal:  Proteomics Clin Appl        ISSN: 1862-8346            Impact factor:   3.494


  6 in total

1.  Identification of novel diagnostic biomarkers for deep venous thrombosis.

Authors:  Ashfaque A Memon; Kristina Sundquist; Mirnabi PirouziFard; Johan L Elf; Karin Strandberg; Peter J Svensson; Jan Sundquist; Bengt Zöller
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

Review 2.  Current applications of artificial intelligence combined with urine detection in disease diagnosis and treatment.

Authors:  Jun Tan; Feng Qin; Jiuhong Yuan
Journal:  Transl Androl Urol       Date:  2021-04

3.  Capillary Electrophoresis: Trends and Recent Advances.

Authors:  Robert L C Voeten; Iro K Ventouri; Rob Haselberg; Govert W Somsen
Journal:  Anal Chem       Date:  2018-01-18       Impact factor: 6.986

Review 4.  Predicting the Risk of Recurrent Venous Thromboembolism: Current Challenges and Future Opportunities.

Authors:  Hannah Stevens; Karlheinz Peter; Huyen Tran; James McFadyen
Journal:  J Clin Med       Date:  2020-05-22       Impact factor: 4.241

5.  New biomarkers of Kawasaki disease identified by urine proteomic analysis.

Authors:  Hui-Min Hu; Hong-Wu Du; Jia-Wen Cui; De-Qin Feng; Zhong-Dong Du
Journal:  FEBS Open Bio       Date:  2018-12-20       Impact factor: 2.693

6.  Elucidation of a Human Urine Metabolite as a Seryl-Leucine Glycopeptide and as a Biomarker of Effective Anti-Tuberculosis Therapy.

Authors:  Bryna L Fitzgerald; M Nurul Islam; Barbara Graham; Sebabrata Mahapatra; Kristofor Webb; W Henry Boom; Stephanus T Malherbe; Moses L Joloba; John L Johnson; Jill Winter; Gerhard Walzl; John T Belisle
Journal:  ACS Infect Dis       Date:  2019-01-10       Impact factor: 5.084

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.